Digitising the cell to discover new drugs
Engine Biosciences uses data analytics and machine learning to speed up the discovery of new drugs.
THE current state of medical technology has meant that despite there being some 20,000 genes in the human genome, the standard procedure for drug discovery is to laboriously measure the effect of a test drug on a single or pair of genes one by one.
Each individual or pair of genes has to be examined, which would theoretically mean conducting an excess of 20,000 tests for individual genes, and an additional 400 million tests for pairs of genes.
The trial-and-error approaches have been summarised by Engine Biosciences co-founder and chief executive officer Jeffrey Lu as: brute-force hacking or old-fashioned quests.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Nestle sales growth sputters on US slump, vitamin snags
BNP Paribas beats estimates as lower costs offset trading slump
TikTok ultimatum puts US firms in firing line for China response
Toyota and Nissan pair up with Tencent and Baidu for China AI arms race
BHP targets Anglo American in bid valuing miner at US$39 billion
FTSE 100 hits record high on big mining M&A, earnings push